Statins - increasing or reducing the risk of Parkinson's disease?
Experimental Neurology , Volume 228 - Issue 1 p. 1- 4
|Keywords||1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine, Parkinson disease, alpha synuclein, antioxidant activity, atorvastatin, brain derived neurotrophic factor, cholesterol, cholesterol blood level, cholesterol synthesis, cyclic AMP responsive element binding protein, cytokine production, diffuse Lewy body disease, disease model, dopamine, dopamine 1 receptor, dopamine 2 receptor, drug efficacy, drug megadose, drug withdrawal, dyskinesia, enzyme activation, enzyme synthesis, fluindostatin, human, hydroxymethylglutaryl coenzyme A reductase, hydroxymethylglutaryl coenzyme A reductase inhibitor, immunoglobulin enhancer binding protein, ischemic heart disease, lipid raft, low density lipoprotein cholesterol, medical research, meta analysis (topic), methodology, mevalonic acid, mevinolin, mitochondrial respiration, mitogen activated protein kinase 1, mitogen activated protein kinase 3, multicenter study (topic), muscle rigidity, nerve degeneration, neuroprotection, nonhuman, note, outcome assessment, parkinsonism, peroxynitrite, phase 2 clinical trial (topic), pitavastatin, placebo, pravastatin, priority journal, protein aggregation, protein kinase B, protein p21, randomized controlled trial (topic), risk reduction, rosuvastatin, sample size, signal transduction, simvastatin, tremor, tumor necrosis factor alpha, tumor necrosis factor receptor 2, ubidecarenone, unindexed drug|
|Persistent URL||dx.doi.org/10.1016/j.expneurol.2010.11.013, hdl.handle.net/1765/23114|
Dolga, A.M., Culmsee, C., de Lau, L., Winter, Y., Oertel, W., Luiten, P.G.M., & Eisel, U.L.M.. (2011). Statins - increasing or reducing the risk of Parkinson's disease?. Experimental Neurology, 228(1), 1–4. doi:10.1016/j.expneurol.2010.11.013